Skip to main content

Table 2 Overall mortality of the study patients compared to that of the male population of Finland

From: Survival and mortality of elderly men with localized prostate cancer managed with primary androgen deprivation therapy or by primary observation

All patients

Period

1985–1994

1995–2004

2005–2014

ADT

Observation

ADT

Observation

ADT

Observation

Age

SMR (95% confidence interval)

All (> 70)

1.48 (1.41–1.54)

1.20 (1.10–1.30)

1.19 (1.15–1.23)

1.03 (0.98–1.08)

1.08 (1.03–1.13)

0.93 (0.88–0.98)

70–79

1.57 (1.48–1.65)

1.17 (1.05–1.30)

1.24 (1.19–1.29)

1.05 (0.99–1.11)

1.11 (1.04–1.19)

0.95 (0.88–1.01)

≥80

1.39 (1.22–1.42)

1.25 (1.08–1.43)

1.10 (1.04–1.17)

1.00 (0.92–1.09)

1.04 (0.97–1.11)

0.89 (0.82–0.97)

Matched pairs

 All (> 70)

1.50 (1.38–1.63)

1.19 (1.09–1.30)

1.19 (1.13–1.25)

1.03 (0.98–1.08)

1.09 (1.03–1.15)

0.93 (0.87–0.98)

 70–79

1.57 (1.41–1.74)

1.16 (1.04–1.29)

1.23 (1.16–1.30)

1.05 (0.99–1.11)

1.12 (1.05–1.20)

0.94 (0.87–1.01)

  ≥ 80

1.39 (1.21–1.60)

1.25 (1.08–1.44)

1.12 (1.02–1.21)

1.00 (0.91–1.08)

1.03 (0.94–1.12)

0.91 (0.82–0.99)

  1. Population mortality stratified by age and calendar year and education level
  2. ADT androgen deprivation therapy, SMR standardized mortality ratio